BALTIMORE, MD, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Greater Cannabis Company (OTCQB: GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems and cannabinoids products is proud to announce that is has advanced its cannabidiol research study with researchers from Hadassah Hebrew University Hospital and Research Center.
The first cooperative effort involves studying different formulations of cannabidiol (CBD) using Greater Cannabis’ innovative delivery platform, which has been successful in achieving 40-50% bioavailability using different active pharmaceutical ingredients (APIs). The study will help further substantiate the significance of the eluting transmucosal patch (ETP) platform, and advance a number of ongoing discussions the Company has with pharmaceutical and cannabis companies.
The researchers involved in the study stem from the Hebrew University Cannabis Research Center, the home of Dr. Rephael Mechoulam, “father of cannabis”, and other renowned researchers. They have decades of experience in cannabis research, and have published hundreds of publications on the subject in leading journals. “We have identified and partnered with the most experienced cannabis researchers in the World who were studying the effects of CBD years before it became a popular product”, said Aitan Zacharin, CEO of the Greater Cannabis Company. “With the knowledge we have that our delivery platform is an incredibly effective way of administering cannabinoids, we knew that we needed the top teams in the industry to work on developing and executing our study protocols. With this data we intend to further substantiate our claims, and advance the clinical applications of our technology, while continuing in parallel paths with the commercialization of our products.”
About The Greater Cannabis Company
The Greater Cannabis Company (OTC: GCAN) is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems. Greater Cannabis deploys its patented technology platform for use in the cannabis industry. The Company’s conveyance platform can be utilized to deliver cannabinoids without the harmful side effects found with other routes of cannabinoid administration. The technology is versatile in that for the first-time patients can receive lower dosing, enhanced bioavailability, and controlled rapid and delayed release using a fully dissolvable, non-irritant oral eluting patch. Greater Cannabis’ mission is to bring our technology to the global market through partnerships with leading cannabis and pharmaceutical companies, for the benefit of patients and consumers. More information on the Greater Cannabis Company and its technology can be found on the Company’s website, www.gcanrx.com.
Disclaimer: Greater Cannabis Company Inc relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve several risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.
Contact:
The Greater Cannabis Company, Inc.
443-738-4051
info@gcanrx.com
www.gcanrx.com
###
